Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
about
Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulationCirculating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblastsLL-37 in periodontal health and disease and its susceptibility to degradation by proteinases present in gingival crevicular fluid.A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.Antimicrobial peptide LL-37 along with peptidoglycan drive monocyte polarization toward CD14(high)CD16(+) subset and may play a crucial role in the pathogenesis of psoriasis guttataAntimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment.Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia.High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestineMesenchymal stem cells in tissue repairFortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis.Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses.LPS inmobilization on porous and non-porous supports as an approach for the isolation of anti-LPS host-defense peptides.Cathelicidins Inhibit Escherichia coli-Induced TLR2 and TLR4 Activation in a Viability-Dependent Manner.Msb2 shedding protects Candida albicans against antimicrobial peptidesPotential role of an antimicrobial peptide, KLK in inhibiting lipopolysaccharide-induced macrophage inflammation.Candida albicans mucin Msb2 is a broad-range protectant against antimicrobial peptides.Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs.The yin and yang of human Beta-defensins in health and diseaseCo-administration of Antimicrobial Peptides (AMPs) EnhancesToll-like Receptor 4 (TLR4) Antagonist Activity of a Synthetic Glycolipid.Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.What is the role of antimicrobial peptides (AMP) in acne vulgaris?Goat cathelicidin-2 is secreted by blood leukocytes regardless of lipopolysaccharide stimulation.Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells.Cathelicidins: Immunomodulatory Antimicrobials
P2860
Q28534617-A8256E73-D626-49DD-A5C1-66B2EE86348FQ33667766-751E8A10-A4BB-48E6-8B95-D3534D55D3BEQ34489424-7212DE7B-9762-4EB7-AAEF-CC7D8157F4B3Q34757218-A8E0A28E-8711-4AB3-8168-5F40818BCDD1Q34952815-2083D578-C0DE-4500-8884-B437965867C2Q35591399-52CC9086-0A7A-455A-82E2-62C773B66F40Q35941306-A87B9400-7FD6-4409-97E2-3C7363353EA3Q36559330-0DAD036F-9D86-4DBA-B834-219831803097Q36593572-12960098-6EC9-4FF7-89A0-2DF2DC8B1F43Q36903462-26AFA803-54A1-4C18-8242-F9E2A876C41CQ37142817-00932543-FAE6-4D40-A9A0-FDD225FDC373Q38113080-21EE3A4B-174F-4C85-A6E8-AA03147228BCQ38152470-F04F4174-190A-4BA2-820D-B7E30333994BQ38177267-943036B7-C7E8-492F-BEEC-2EB70AC21DDBQ40134037-4F79DA04-29D7-40A6-8B84-21B11C90BFECQ40812978-84347C49-5F04-4951-BB4C-0567A6104BE6Q41545553-6BC8A3C1-5023-4244-95E6-357E53EE1CF4Q42021694-39AF4AAF-F132-4515-9935-7A91468CA19FQ42424399-C42E406F-E11E-440F-A429-0D9149D137BDQ42473672-14E341DC-68D2-4153-B013-82810D5F7CE1Q47266793-4AF95568-8D06-4A7D-AABB-64C2DB9170DBQ47855388-3EA0428E-2FE7-48BA-A419-B437F2FC6728Q50957903-F40913C3-DE7E-41F4-AE94-704556F42607Q53407510-DDC0FCDF-0905-4AF2-A8A8-F2DA0C91ADB4Q55010741-78CC5EA6-DB18-4346-B18D-EF2E09D1F3FEQ58739098-2243E676-6FB6-4A9B-B564-2ECE8DAFE3D0
P2860
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@ast
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@en
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@nl
type
label
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@ast
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@en
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@nl
prefLabel
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@ast
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@en
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
@nl
P2093
P2860
P50
P1433
P1476
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo
@en
P2093
Bettina Schock
Chris R Irwin
Paul J Buchanan
Robert K Ernst
P2860
P304
P356
10.1371/JOURNAL.PONE.0026525
P407
P577
2011-10-18T00:00:00Z